Emma Lawson
A patient of mine, someone I’d been working with for about three years on fatigue management, sent me a screenshot in March 2026 with one message: “Did you see the ACTRIMS presentation?” She’d been living with relapsing-remitting MS for a decade. She’d tried nearly every dietary approach her neurologist would entertain. And she’d heard about ketogenic diets before, mostly from Facebook groups where the claims get… ambitious. But something about this felt different to her. It felt like the science was actually catching up.
She wasn’t wrong. The past twelve months have produced a cluster of MS-specific keto research that genuinely shifts the conversation. Not “keto cures MS.” Not that. But the signal is real, it’s consistent across multiple study types, and anyone with MS who’s curious about dietary intervention deserves a clear-eyed look at what we actually know right now.
What the Recent Research Actually Found
Let’s start with the study most people are talking about. The UVA Health Phase II trial enrolled 65 adults with relapsing-remitting MS and put them on a ketogenic diet. After six months, participants walked farther and faster on the six-minute walk test, showed improved fine motor speed, reduced total body fat, and reported better fatigue, depression, and quality-of-life scores. These aren’t soft biomarkers. Walking speed and the six-minute walk distance are standard clinical outcomes in MS trials. Neurologists care about those numbers.
Then there’s the ACTRIMS Forum data. A study presented at the February-March 2025 meeting in West Palm Beach showed that a modified Atkins diet produced measurable immunomodulatory effects in MS patients after six months, with altered immune cell metabolism. The researchers framed it as an adjunct to disease-modifying therapy, not a replacement. That framing matters.
A 2025 systematic review published in Cureus (DOI: 10.7759/cureus.89965) synthesized six studies from 2017 through 2024 and found consistent patterns: reduced levels of pro-inflammatory markers including ALOX5, COX1, and COX2, along with improved scores on the Expanded Disability Status Scale, better walking ability, and better manual dexterity in relapsing-remitting MS patients. Six studies isn’t a mountain of evidence. But consistency across independent research teams matters more than people realize.
The Composition Problem Nobody Is Talking About
Here’s where I want to slow down, because this part gets lost in the headlines.
A University of Iowa preclinical study published in Frontiers in Immunology in May 2025 introduced something uncomfortable: a high-saturated, long-chain fatty acid ketogenic diet actually worsened visual and motor-sensory function in an MS mouse model. Not a little worse. Measurably worse.
This is significant. It means “keto” is not one thing. A diet built around butter, beef tallow, and coconut oil has a very different fatty acid profile than one built around olive oil, avocado, and fatty fish. The carbohydrate restriction might be identical. The ketone production might be similar. But the inflammatory effect of the fat sources appears to matter, possibly a great deal, in an autoimmune context.
This is why the EDQ-MS trial, which is currently enrolling participants, specifically uses an olive oil-based ketogenic diet combined with time-restricted eating. The researchers aren’t just restricting carbs. They’re controlling fat composition too, with MRI, microbiome, and metabolome endpoints at six and twenty-four months. That’s the kind of rigorous design the field has needed.
For anyone with MS who wants to try keto now, before those results are in, the preclinical signal suggests leaning toward monounsaturated and omega-3 fats, olive oil, avocado oil, salmon, sardines, walnuts, rather than building the diet around saturated animal fats. That’s not guaranteed guidance. It’s a reasonable inference from the available data.
How the Outcomes Stack Up
The studies measured different things, which makes direct comparison messy. But it helps to see what kinds of improvements showed up and across what timeframes.
| Outcome Measured | Study / Source | Timeframe | Direction |
|---|---|---|---|
| EDSS (disability score) | Cureus systematic review, 2025 | Varies by study | Improved |
| 6-minute walk distance and speed | UVA Health Phase II trial | 6 months | Improved |
| Fine motor speed | UVA Health Phase II trial | 6 months | Improved |
| Fatigue and depression scores | UVA Health Phase II trial | 6 months | Improved |
| Pro-inflammatory markers (ALOX5, COX1, COX2) | Cureus systematic review, 2025 | Varies by study | Reduced |
| Immune cell metabolism | ACTRIMS 2025 modified Atkins study | 6 months | Altered (immunomodulatory) |
| Visual and motor-sensory function | U. Iowa mouse model (Frontiers in Immunology, May 2025) | Preclinical | Worsened (high saturated fat KD) |
That last row is the one that keeps me from being too enthusiastic. Mouse models don’t always translate to humans. But they’re not noise, either.
The Practical Reality for MS Patients Considering This
About 2.3 million people worldwide live with MS, and most of them have already looked into dietary interventions. The motivation is entirely understandable. There’s no cure, disease-modifying therapies work differently for different people, and the side effect burdens can be real. Of course people look at their plates.
What most people don’t realize is how much the keto research in MS has been built on small, short-term studies with limited controls. The systematic review in Cureus was clear about this limitation. Six studies, most of them observational or pilot-scale, with varying dietary protocols. The UVA trial is the most rigorous human data we have so far, and even that was a single-arm study without a randomized control group for comparison.
What this means practically: the signal is promising enough to discuss seriously with your neurologist, and weak enough that going rogue with a strict keto protocol without medical supervision is genuinely risky for someone on immunomodulating drugs, or someone who has comorbidities affecting their lipid metabolism or kidney function. This is a population that often has complex medication lists. Dietary changes that affect inflammation, metabolism, and gut microbiome composition can interact with those medications in ways that aren’t fully mapped yet.
I’d also be honest about the tolerability issue. Keto isn’t easy to maintain, and neurological fatigue plus keto flu during the adaptation period can be a rough combination. I’ve seen people bail in week two not because keto wasn’t working but because they had no support structure and felt awful before the benefits appeared. If you try this, have a dietitian in your corner who knows both the ketogenic approach and the MS context.
What to Watch For in the Coming Months
The EDQ-MS trial results will be worth following closely, particularly the MRI and microbiome data. If dietary fat composition shows up as a meaningful variable in human MS patients, the way it did in the Iowa mouse model, it will force a significant rethinking of how keto protocols are designed for autoimmune conditions. The NeurologyLive reporting from June 2026 is already flagging immune cell metabolism as the mechanism researchers are most focused on, which suggests the next round of studies will get more specific about which aspects of ketogenic metabolism are driving the effects.
The research is moving faster now than it was even two years ago. That’s genuinely good news for the 2.3 million people waiting for better answers. For now, the honest summary is this: there’s enough real evidence to take keto seriously as a potential adjunct in MS management, enough uncertainty to approach it carefully, and enough variation in how these diets are constructed to make “keto” mean very different things for your health outcomes. Work with your care team. Watch the composition of the fats, not just the carb count. And be appropriately skeptical of anyone, on any side of this debate, who makes it sound simple.
Sources
- Safety and Efficacy of Ketogenic Diet in the Management of Multiple Sclerosis: A Systematic Review (published 2025, indexed June–July 2026)
- Ketogenic Diet Shows Potential for Modulating Immune Response in MS (June 2026)
- Ketogenic Diet Shows Major Benefits for Multiple Sclerosis (November 2025)
- A High-Saturated, Long-Chain Fatty Acid Ketogenic Diet Negatively Impacts MS Model (May 2025)
- Efficacy of Diet on Quality of Life in Multiple Sclerosis (EDQ-MS) Trial Protocol (2025–2026)
Photo: ROMAN ODINTSOV via Pexels
This article is for general informational purposes only and does not constitute medical or dietary advice. Always consult a licensed healthcare provider or registered dietitian before making significant changes to your diet, especially if you have a medical condition.
